ENAVATE SCIENCES GP LLC
Q4 2025 Form 13-F
NEW YORK, DELAWARE
CIK 0001953107
· Institutional investment manager
$506.8M Reported Value Total
Reported value
$506.8M
Quarter over quarter
+54.4%
Holdings
7
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
James P. Boylan
Chief Executive Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 17, 2026 |
| Form | 13F-HR |
| Reported value | $506.8M |
| Positions | 7 |
| Change in reported value | +54.7% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
7 | $345.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
7 | $351.5M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
7 | $506.8M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
7 | $327.5M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
6 | $176.5M |
|
Q1 2025 13F
Filed May 15, 2025
|
6 | $132.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
5 | $139.2M |
Top 7 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ZBIO ZENAS BIOPHARMA INC | $142.3M | 28.08% |
| 2 | IMNM IMMUNOME INC | $102.4M | 20.21% |
| 3 | SION SIONNA THERAPEUTICS INC | $101.9M | 20.12% |
| 4 | UPB UPSTREAM BIO INC | $66.8M | 13.18% |
| 5 | CMPX COMPASS THERAPEUTICS INC | $41.8M | 8.25% |
| 6 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | $32.9M | 6.49% |
| 7 | CAMP CAMP4 THERAPEUTICS CORP | $18.6M | 3.67% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.